Management
Lloyd M. Segal
Chief Executive Officer
Mr. Segal served as President and CEO of Caprion Pharmaceuticals from 1998 until its merger with Ecopia BioSciences to form Thallion in 2007. He was previously a management consultant with McKinsey & Co. and President and CEO of Advanced Bioconcept Ltd, which was sold to NEN Life Sciences (now Perkin-Elmer) in 1998. Mr. Segal is currently a member of the Board of Directors of Biovail Corporation (NYSE:BVF), and of GBC North American Growth Fund, Inc., one of Canada’s leading small-cap mutual funds. He is also a member of the Board of Overseers of the School of Science, Brandeis University and previously served as a member of the Board of Directors of BIOTECanada, Canada’s national biotechnology industry association. Mr. Segal earned a B.A. in Politics from Brandeis University (Waltham, MA), and an M.B.A. from Harvard Business School (Cambridge, MA).
Pierre Falardeau, Ph.D.
Chief Operating Officer
Dr. Falardeau served as President and CEO of Ecopia BioSciences from 2002 until its merger with Caprion in 2007. His leadership and his experience in the areas of corporate management, and pre-clinical and clinical drug development allowed him to transform Ecopia from a pure platform company into a discovery and development company. In addition, Dr. Falardeau brings a wealth of knowledge and expertise to the Company in the field of oncology. Before joining Ecopia, Dr. Falardeau was Vice-President, Scientific Affairs at Æterna Laboratories (TSX:AEZ). Prior to that, he was an associate professor at Laval University where he established a research team in pharmacology after spending five years at Duke University, North Carolina.
Michael Singer
Chief Financial Officer & Corporate Secretary
Mr. Singer served as Chief Financial Officer and Corporate Secretary of Caprion Pharmaceuticals until its merger with Ecopia BioSciences in 2007. Mr. Singer has 20 years of financial, operational, and accounting experience and, prior to joining Caprion in 2000, was manager at BDO Dunwoody, an international firm of Chartered Accountants. During his eleven years in public practice, Mr. Singer specialized in audit, taxation and client relations. Mr. Singer received a BComm in Finance and Accounting from Concordia University, a degree in Public Accountancy from McGill University Faculty of Graduate Studies and holds a Certified General Accountant designation from the Ordre des CGA du Québec.
Allan Mandelzys, Ph.D.
Executive Vice-President, Licensing & Corporate Development
Dr. Mandelzys served as Vice President, Business Development for Labopharm Inc. from October 2000 to December 2006. He has extensive experience in the areas of pharmaceutical licensing, contract negotiations, strategic alliance management, intellectual property management and scientific operations. Prior to joining Labopharm, Dr. Mandelzys held several positions at Allelix Biopharmaceuticals Inc. (now NPS Pharmaceuticals) beginning with scientific roles of increasing responsibility and culminating as Director, Business Development. Dr. Mandelzys holds both a Ph.D. in physiology and an M.B.A. from McGill University and a B.Sc. from the University of Toronto. He received his post-doctoral training at the Roche Institute of Molecular Biology.
Didier Reymond, MD
Vice President, Medical & Clinical Affairs
Dr. Reymond leads clinical development for all phases ofThallion's clinicalprograms. Before Thallion, he was a Senior Medical Advisorwith Novartis Canada, leading the medical and clinical activities for solid tumors. Prior to that, Dr. Reymond was Associate Director, Scientific Affairs, for the Merck Vaccine Division, Merck Frosst Canada. He was responsible for Regulatory Affairs and Medical Affairs for all vaccines in Canada. Dr. Reymond graduated from Lausanne University, Medical School,before working in Pediatric Surgery and completing his residency in Pediatrics at the University Hospitals of Lausanne and Bern.Board certified in Pediatrics, Dr. Reymond pursued a Fellowship in Pediatric Infectious Diseases at The Hospital for Sick Children, Toronto, where he conducted research activities on Verotoxin-producing Escherichia coli. Dr. Reymond completed his fellowship program at the Hôpital Sainte-Justine, in Montreal, conducting pediatric clinical research focusing on oral antibiotics.